Venkateshwar Chinthalapally
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 9 | 2022 | 121 | 1.970 |
Why?
|
| Adenocarcinoma | 5 | 2022 | 297 | 1.230 |
Why?
|
| Adenoma | 4 | 2021 | 61 | 0.900 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 139 | 0.870 |
Why?
|
| Anticarcinogenic Agents | 4 | 2019 | 16 | 0.840 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2021 | 120 | 0.780 |
Why?
|
| Naproxen | 3 | 2021 | 14 | 0.760 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2021 | 65 | 0.690 |
Why?
|
| Azoxymethane | 7 | 2021 | 20 | 0.670 |
Why?
|
| Aspirin | 4 | 2019 | 124 | 0.670 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 678 | 0.660 |
Why?
|
| Genomic Instability | 4 | 2022 | 34 | 0.630 |
Why?
|
| Apoptosis | 7 | 2021 | 771 | 0.590 |
Why?
|
| Animals | 24 | 2021 | 10399 | 0.560 |
Why?
|
| Signal Transduction | 6 | 2018 | 1433 | 0.550 |
Why?
|
| Mutation | 4 | 2021 | 848 | 0.540 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 63 | 0.540 |
Why?
|
| N-Acetylglucosaminyltransferases | 2 | 2016 | 15 | 0.520 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 164 | 0.510 |
Why?
|
| Lipoxygenase | 2 | 2014 | 3 | 0.490 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2014 | 23 | 0.490 |
Why?
|
| Pancreatic Neoplasms | 3 | 2016 | 534 | 0.440 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 166 | 0.440 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 354 | 0.430 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2015 | 103 | 0.430 |
Why?
|
| Isothiocyanates | 1 | 2013 | 11 | 0.420 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2015 | 164 | 0.410 |
Why?
|
| Carcinoma in Situ | 2 | 2014 | 46 | 0.410 |
Why?
|
| Mice | 14 | 2021 | 4645 | 0.410 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 115 | 0.400 |
Why?
|
| Diet | 2 | 2013 | 231 | 0.400 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 142 | 0.380 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2014 | 135 | 0.380 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 135 | 0.370 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 77 | 0.360 |
Why?
|
| Sea Cucumbers | 2 | 2015 | 2 | 0.360 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2018 | 19 | 0.350 |
Why?
|
| Neoplasms | 3 | 2016 | 818 | 0.330 |
Why?
|
| Alendronate | 1 | 2019 | 6 | 0.330 |
Why?
|
| Metformin | 1 | 2019 | 36 | 0.320 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 58 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 464 | 0.310 |
Why?
|
| Receptors, Enterotoxin | 1 | 2018 | 4 | 0.300 |
Why?
|
| Mice, Transgenic | 6 | 2021 | 509 | 0.300 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 16 | 0.300 |
Why?
|
| Paracrine Communication | 1 | 2018 | 17 | 0.300 |
Why?
|
| Cyclic GMP | 1 | 2018 | 29 | 0.300 |
Why?
|
| Hormones | 1 | 2018 | 43 | 0.300 |
Why?
|
| Adenomatous Polyposis Coli | 3 | 2013 | 10 | 0.290 |
Why?
|
| Humans | 20 | 2022 | 28121 | 0.290 |
Why?
|
| Rats | 6 | 2021 | 1564 | 0.280 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 464 | 0.280 |
Why?
|
| Rats, Inbred F344 | 5 | 2021 | 170 | 0.280 |
Why?
|
| Genes, APC | 3 | 2015 | 14 | 0.280 |
Why?
|
| Chromosomal Instability | 2 | 2015 | 21 | 0.270 |
Why?
|
| Mitosis | 3 | 2015 | 111 | 0.270 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 7 | 0.270 |
Why?
|
| Mucins | 1 | 2016 | 24 | 0.270 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 187 | 0.260 |
Why?
|
| Carcinogens | 4 | 2021 | 39 | 0.260 |
Why?
|
| Chromosome Segregation | 2 | 2009 | 55 | 0.260 |
Why?
|
| Curcumin | 1 | 2007 | 69 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 330 | 0.250 |
Why?
|
| Mucin-1 | 1 | 2016 | 35 | 0.250 |
Why?
|
| Muscles | 1 | 2015 | 73 | 0.240 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2015 | 133 | 0.240 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 82 | 0.240 |
Why?
|
| Eflornithine | 1 | 2014 | 3 | 0.230 |
Why?
|
| Ornithine Decarboxylase | 1 | 2014 | 9 | 0.230 |
Why?
|
| Drug Delivery Systems | 2 | 2016 | 225 | 0.230 |
Why?
|
| Uroplakin II | 1 | 2014 | 5 | 0.220 |
Why?
|
| Cell Proliferation | 5 | 2019 | 804 | 0.220 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2014 | 5 | 0.220 |
Why?
|
| Pyrroles | 1 | 2014 | 36 | 0.220 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2013 | 8 | 0.220 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2013 | 5 | 0.220 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 16 | 0.210 |
Why?
|
| Escin | 1 | 2013 | 1 | 0.210 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2013 | 8 | 0.210 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2013 | 24 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 131 | 0.210 |
Why?
|
| rho-Associated Kinases | 1 | 2013 | 12 | 0.210 |
Why?
|
| Male | 11 | 2021 | 13487 | 0.210 |
Why?
|
| Antimitotic Agents | 1 | 2012 | 5 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 605 | 0.200 |
Why?
|
| Chemoprevention | 3 | 2018 | 32 | 0.200 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 1324 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 4 | 2015 | 67 | 0.200 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 55 | 0.200 |
Why?
|
| Plant Extracts | 2 | 2018 | 64 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 190 | 0.190 |
Why?
|
| Biological Products | 1 | 2012 | 65 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 326 | 0.180 |
Why?
|
| Female | 10 | 2021 | 15156 | 0.180 |
Why?
|
| Blotting, Western | 4 | 2015 | 510 | 0.170 |
Why?
|
| RNA, Messenger | 4 | 2015 | 656 | 0.170 |
Why?
|
| Intestinal Neoplasms | 2 | 2015 | 15 | 0.160 |
Why?
|
| Microtubules | 1 | 2009 | 91 | 0.150 |
Why?
|
| Carcinogenesis | 2 | 2013 | 84 | 0.150 |
Why?
|
| Momordica charantia | 1 | 2018 | 1 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 5 | 2015 | 1570 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2008 | 126 | 0.140 |
Why?
|
| Disease Progression | 3 | 2014 | 473 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 270 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 207 | 0.130 |
Why?
|
| Acetates | 1 | 2006 | 45 | 0.130 |
Why?
|
| Dinoprostone | 2 | 2021 | 42 | 0.120 |
Why?
|
| Indoles | 1 | 2006 | 99 | 0.120 |
Why?
|
| Complex Mixtures | 1 | 2015 | 12 | 0.120 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 24 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2005 | 158 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 3 | 2013 | 68 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2014 | 315 | 0.110 |
Why?
|
| Aberrant Crypt Foci | 1 | 2013 | 2 | 0.100 |
Why?
|
| alpha-Linolenic Acid | 1 | 2013 | 4 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2015 | 225 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 38 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2022 | 82 | 0.100 |
Why?
|
| Omeprazole | 1 | 2021 | 9 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 406 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 27 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 29 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 103 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1461 | 0.090 |
Why?
|
| Transcriptome | 1 | 2022 | 214 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 136 | 0.090 |
Why?
|
| Alleles | 1 | 2021 | 353 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 149 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2012 | 40 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2019 | 104 | 0.080 |
Why?
|
| beta Catenin | 2 | 2012 | 66 | 0.080 |
Why?
|
| Rats, Wistar | 1 | 2019 | 151 | 0.080 |
Why?
|
| Lung | 1 | 2022 | 375 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2019 | 189 | 0.080 |
Why?
|
| Celecoxib | 1 | 2018 | 10 | 0.080 |
Why?
|
| Hemostasis | 1 | 2018 | 48 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 74 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 75 | 0.070 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2007 | 16 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 25 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 49 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2007 | 86 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2016 | 63 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2007 | 243 | 0.060 |
Why?
|
| Polyamines | 1 | 2015 | 13 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 249 | 0.060 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2015 | 2 | 0.060 |
Why?
|
| Glypicans | 1 | 2015 | 3 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2016 | 289 | 0.060 |
Why?
|
| alpha-Fetoproteins | 1 | 2015 | 18 | 0.060 |
Why?
|
| Transfection | 1 | 2016 | 318 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 179 | 0.060 |
Why?
|
| Haploinsufficiency | 1 | 2015 | 8 | 0.060 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 31 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2015 | 16 | 0.060 |
Why?
|
| Sirolimus | 1 | 2015 | 76 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 68 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2015 | 118 | 0.060 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 2014 | 2 | 0.060 |
Why?
|
| Hepacivirus | 1 | 2015 | 48 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 49 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 411 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2015 | 208 | 0.060 |
Why?
|
| Models, Biological | 1 | 2007 | 465 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 126 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2013 | 24 | 0.050 |
Why?
|
| Nitrosamines | 1 | 2013 | 5 | 0.050 |
Why?
|
| DNA Damage | 1 | 2015 | 149 | 0.050 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 10 | 0.050 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 14 | 0.050 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 33 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 104 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 90 | 0.050 |
Why?
|
| Tobacco | 1 | 2013 | 87 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2012 | 19 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2012 | 38 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 345 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2013 | 288 | 0.050 |
Why?
|
| Integrases | 1 | 2012 | 39 | 0.050 |
Why?
|
| Cell Movement | 1 | 2014 | 369 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2015 | 985 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 68 | 0.050 |
Why?
|
| Body Weight | 1 | 2012 | 250 | 0.050 |
Why?
|
| Inflammation | 1 | 2015 | 626 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 825 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2009 | 2 | 0.040 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2009 | 4 | 0.040 |
Why?
|
| Mad2 Proteins | 1 | 2009 | 10 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 61 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2009 | 52 | 0.040 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 18 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2008 | 57 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 29 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2008 | 22 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 76 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2009 | 118 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 123 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 247 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 2015 | 10 | 0.030 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 58 | 0.030 |
Why?
|
| Colonic Polyps | 1 | 2005 | 17 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 2015 | 57 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2015 | 79 | 0.030 |
Why?
|
| Aged | 1 | 2013 | 5416 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 165 | 0.030 |
Why?
|
| Gene Expression | 1 | 2005 | 414 | 0.030 |
Why?
|
| Corn Oil | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cyclooxygenase 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Plant Oils | 1 | 2013 | 10 | 0.030 |
Why?
|
| Cytokines | 1 | 2015 | 445 | 0.020 |
Why?
|
| Middle Aged | 1 | 2013 | 7164 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 197 | 0.020 |
Why?
|
| Adult | 1 | 2013 | 7757 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2013 | 485 | 0.020 |
Why?
|